Current status of taxane and platinum-based chemotherapy in ovarian cancer.
Current status of taxane and platinum-based chemotherapy in ovarian cancer.
复制标题
卵巢癌紫杉烷和铂类化疗的现状。
DOI：
10.1200/jco.2003.01.066
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
W. Mcguire
中科院分区：
文献类型：
--
作者：
W. Mcguire
1993年以前，晚期卵巢癌化疗管理的标准治疗是顺铂或卡铂联合经典烷化剂（通常为环磷酰胺）。20世纪90年代的研究将该标准改为含铂药物与紫杉烷、紫杉醇或多西他赛的组合。本文回顾了紫杉醇联合顺铂或卡铂的相关研究，讨论了围绕如何最好地联合收割机这些药物的剩余争议，并提供了关于紫杉醇-铂双联研究中注意到的不一致结果的意见。另一篇文章讨论了紫杉醇-铂双药疗法，以及如何将其视为晚期新诊断卵巢癌患者一线治疗的适当选择。
Before 1993, the standard of care for the chemotherapeutic management of advanced ovarian cancer was cisplatin or carboplatin combined with a classic alkylating agent (typically cyclophosphamide). Studies in the 1990s have changed this standard to one of the platinum-containing agents combined with a taxane, paclitaxel, or docetaxel. This article reviews the pertinent studies regarding paclitaxel combined with cisplatin or carboplatin, discusses the remaining controversies surrounding how best to combine these agents, and provides opinions regarding the discordant outcomes noted in studies of the paclitaxel-platinum doublet. A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer.